390 related articles for article (PubMed ID: 36719646)
21. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer.
Weber M; Hadaschik B; Ferdinandus J; Rahbar K; Bögemann M; Herrmann K; Fendler WP; Kesch C
Eur Urol Focus; 2021 Mar; 7(2):279-287. PubMed ID: 33483289
[TBL] [Abstract][Full Text] [Related]
23. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B
BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367
[TBL] [Abstract][Full Text] [Related]
24. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N
Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624
[TBL] [Abstract][Full Text] [Related]
25. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
[TBL] [Abstract][Full Text] [Related]
26. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease.
Henriquez I; Spratt D; Gómez-Iturriaga A; Abuchaibe O; Couñago F
World J Clin Oncol; 2021 Jan; 12(1):6-12. PubMed ID: 33552935
[TBL] [Abstract][Full Text] [Related]
27. [Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer].
Kretschmer A; Tilki D
Urologe A; 2019 May; 58(5):529-534. PubMed ID: 30887058
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
[TBL] [Abstract][Full Text] [Related]
30. "Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".
Jardim DL; Gonçalves E Silva A; Pompeo ASFL; Sarkis AS; Cardoso APG; Sasse AD; Fay AP; Soares A; Pompeo ACL; Carneiro A; Kann AG; Fogassa C; De Freitas CH; Chade DC; Herchenhorn D; De Almeida DVP; Da Rosa DAR; Wiermann EG; Schutz FAB; Kater FR; De Moura F; Korkes F; Meyer F; De Oliveira FNG; Sabino F; Almeida GL; Avanço G; Guimaraes GC; Lemos GC; Carvalhal GF; Kim H; Morbeck IP; Campagnari JC; Rinck JA; Da Ponte JRT; Da Trindade KM; Atem L; Borges L; Nogueira LM; Batista LTEA; Maia MC; Sadi MV; Rocha MAA; Luz MA; Smaletz O; Lages PSM; Matuda RMK; Reis RBD; Indio RF; Fernandes RC; Cavallero SR; Souza VC; Busato W; Alfer W; Maluf F
Clin Genitourin Cancer; 2023 Apr; 21(2):e58-e69. PubMed ID: 36266221
[TBL] [Abstract][Full Text] [Related]
31. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
32. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
33.
Fourquet A; Aveline C; Cussenot O; Créhange G; Montravers F; Talbot JN; Gauthé M
Sci Rep; 2020 Feb; 10(1):2104. PubMed ID: 32034191
[TBL] [Abstract][Full Text] [Related]
34. Current treatment of non-metastatic castration-refractory prostate cancer.
Büchler T
Klin Onkol; 2021; 34(3):185-191. PubMed ID: 34362254
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
[TBL] [Abstract][Full Text] [Related]
36. Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management.
Tartarone A; Lerose R; Tartarone M
Med Oncol; 2022 May; 39(7):107. PubMed ID: 35553247
[TBL] [Abstract][Full Text] [Related]
37. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
39. The role of Ga
Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
[TBL] [Abstract][Full Text] [Related]
40. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective.
Ingrosso G; Bottero M; Becherini C; Caini S; Alì E; Lancia A; Ost P; Sanguineti G; Siva S; Zilli T; Francolini G; Bellavita R; Aristei C; Livi L; Detti B
Semin Oncol; 2022 Oct; 49(5):409-418. PubMed ID: 36192243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
